Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers February 27, 2015
Pharmacy Choice - Pharmacy News - February 27, 2015

Pharmacy News

Today's Pharmaceutical and Pharmacy News
Daily News Topic:

FDA News
2/27/15 - Actavis: FDA OKs LILETTA To Prevent Pregnancy For Up To 3 Years
WASHINGTON- Actavis plc, a global specialty pharmaceutical company, and Medicines360, a nonprofit women's health pharmaceutical company, today announced the approval of LILETTA by the U.S. Food and Drug Administration or FDA for use by women to prevent pregnancy for up to three years. Actavis and Medicines360's groundbreaking partnership would allo
2/27/15 - Archroma receives FDA approval for Cartaguard KST additive [EMBIN (Emerging Markets Business Information News]
Switzerland- based color and specialty chemicals company Archroma has received FDA approval for the use of its new Cartaguard KST additive in the manufacture of paper and board for food packaging. The product has been approved by the US Federal Food and Drug Administration under 21 CFR 176.170 and can be used as a grease resistance treatment before
2/27/15 - FDA Approves Allerganâ??s NATRELLE INSPIRAâ?¢ Round Gel-Filled Breast Implants
Allergan, Inc. today announced that the company has received approval from the U.S. Food and Drug Administration to market NATRELLE INSPIRAâ?¢ round gel-filled smooth breast implants. â??The FDA approval of NATRELLE INSPIRAâ?¢ round gel-filled implants exemplifies our commitment to scientific innovation and to meeting the dynamic needs of plastic s
2/27/15 - FDA Okays Allergan's Natrelle Inspira Round Gel-Filled Breast Implants
WASHINGTON- Allergan Inc. announced that it has received approval from the U.S. Food and Drug Administration or FDA to market Natrelle Inspira round gel-filled smooth breast implants. The FDA approval of Natrelle Inspira round gel-filled smooth breast implants marks the most recent addition to the broad portfolio of currently available Natrelle...
2/27/15 - Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences
Immunovaccine Inc., a clinical stage vaccine and immunotherapy company, today announced that the U.S. Food and Drug Administration has approved its application for Fast Track designation and Phase I clinical trials of the DPX-Anthrax and DPX-Ebola vaccines, in conjunction with the mutual co-development agreement signed with Gilead Life Sciences.
2/27/15 - LENVIMAâ?¢ (lenvatinib) Now Available Through Two Specialty Pharmacies, Accredo and Biologics, Inc.
Priority Review is designated for drugs that the FDA believes have the potential to provide a significant improvement of a serious condition. "Eisai is dedicated to innovative science and patient care," said David Trexler, Senior Vice President, Eisai Oncology Business Unit, Eisai Inc. "We are pleased to introduce LENVIMA, a new treatment option t

Chain Drug Review
Chain Drug Review Magazine Chain Drug Review, established in 1978 and published 21 times a year, is recognized as the premier news publication serving the entire chain drug store industry.
Featured Article from Chain Drug Review:
AWP suit settlement appealed
The National Association of Chain Drug Stores has appealed a U.S. District Court’s approval of settlements in the First DataBank Inc. and Medi-Span Inc. lawsuit. »read more

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Lupus: What You Need to Know
This lesson is supported by:
Drug Therapy Management Series Part II: Psychiatric Disorders
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement